Povidone
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Povidone: From Dry Eye Syndrome to Congenital Ichthyosiform Erythroderma
One-Sentence Summary
Povidone is a hydrophilic polymer used in lubricating eye drops, originally indicated for dry eye syndrome and xerophthalmia. The TxGNN model predicts it may be effective for congenital ichthyosiform erythroderma, but there are currently no clinical trials and no publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Dry eye syndrome; xerophthalmia |
| Predicted New Indication | Congenital ichthyosiform erythroderma |
| TxGNN Prediction Score | 99.11% |
| Evidence Level | L5 |
| UK Market Status | Marketed |
| Number of Marketing Authorisations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, povidone is a hydrophilic polymer with humectant and film-forming properties. Its use in dry eye relates to surface lubrication rather than to any disease-modifying action.
A speculative link is that these properties could, in theory, support hydration of a dry surface, whether ocular or skin. However, congenital ichthyosiform erythroderma is a genetic disorder of epidermal barrier function and lipid metabolism (for example, mutations in TGM1, ALOXE3, ALOX12B and NIPAL4). Nothing in the data compiled for this report shows that povidone acts on these keratinisation defects.
The high TxGNN score is a knowledge-graph prediction only. It should be treated as a hypothesis for further investigation, not as evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
| Marketing Authorisation Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 1108010T0BBAAAA | Oculotect Eye Drops 5% 0.4ml Unit Dose, preservative-free | Eye drops | Not stated in the data compiled |
| 1108010T0AAAAAA | Povidone K 25 Eye Drops 5% 0.4ml Unit Dose, preservative-free | Eye drops | Not stated in the data compiled |
Both listings are single-ingredient products with valid status. The identifiers shown appear to be BNF-style product codes rather than standard MHRA “PL” numbers, so please verify them against the MHRA register.
Safety Considerations
The data compiled for this report contains no label-based warnings or contraindications, and no drug interactions were found in the interaction query.
The knowledge graph links povidone to the following conditions as contraindication edges. These are model-derived associations, not label text, and they should be interpreted with caution given that the product is an ophthalmic preparation:
- Epilepsy
- Liver disease
- Gallbladder disease
- Respiratory failure
- Atrioventricular block and atrioventricular dissociation (including heart block)
Please refer to the SmPC and BNF for authoritative safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a knowledge-graph score. There are no trials or publications, the mechanism of action is unavailable, and the proposed link to a genetic keratinisation disorder is biologically implausible for a lubricating polymer.
To proceed, the following is needed:
- Mechanism of action data (for example, from DrugBank)
- Label warnings and contraindications from the SmPC and BNF, which are currently missing and block safety screening
- Preclinical or literature evidence of benefit in ichthyosis models or patients
- Assessment of route compatibility, as the current products are ophthalmic and no topical dermatological formulation has been identified
- Approved indication text and dosage form details for the UK authorisations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.